Stay updated on DLL3-Expressing Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the DLL3-Expressing Advanced Cancer Clinical Trial page.

Latest updates to the DLL3-Expressing Advanced Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page has been updated to reflect a new study involving gocatamig, replacing the previous study on MK-6070. Key details include dosing schedules and pharmacokinetic parameters for gocatamig, which are critical for understanding the treatment's administration and effects.SummaryDifference3%
- Check32 days agoNo Change Detected
- Check39 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
- Check47 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.2%
- Check54 days agoChange DetectedDifference0.2%
- Check61 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check68 days agoChange DetectedThe website has updated its contact information for several principal investigators, including the addition of new contacts like Christopher De Leon and the removal of previous principal investigators, while also updating the revision from v2.13.3 to v2.14.0.SummaryDifference4%
Stay in the know with updates to DLL3-Expressing Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DLL3-Expressing Advanced Cancer Clinical Trial page.